Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Eplontersen sodium?

See the DrugPatentWatch profile for Eplontersen

What is eplontersen sodium?

Eplontersen sodium is a prescription medicine intended for use in people with a specific form of hereditary transthyretin amyloidosis (hATTR amyloidosis). It works by targeting the production of transthyretin (TTR), a protein implicated in the condition. [1]

How does eplontersen sodium work?

Eplontersen sodium is designed to reduce the amount of transthyretin made by the body. Lowering circulating TTR helps address the buildup of amyloid formed from misfolded TTR proteins, which drives symptoms and organ damage in hATTR amyloidosis. [1]

What is eplontersen sodium used for?

It is used in people diagnosed with hereditary transthyretin amyloidosis (hATTR), where transthyretin aggregation and amyloid deposition cause progressive disease. [1]

Is eplontersen sodium a brand name or generic?

"Eplontersen sodium" refers to the drug substance (the active ingredient), typically associated with a specific branded product in different markets. Brand names can vary by country. [1]

What would patients usually want to know before using it?

People commonly look for practical details such as how it is given, how it is monitored, what side effects to expect, and how treatment compares with other hATTR therapies. Those specifics depend on the approved prescribing information in the patient’s country. [1]

Where to find the most reliable details (dose, side effects, monitoring)

For the most accurate guidance on dosing, administration, warnings, drug interactions, and required monitoring, the prescribing information for the approved eplontersen product in your region is the best source. [1]

Sources:
[1] https://www.drugs.com/international/eplontersen-sodium.html



Other Questions About Eplontersen :

How does Eplontersen treat polyneuropathy? Eplontersen pronounce? Eplontersen mechanism of action? What is eplontersen?

AI-Drug Label Prescribing Information Alignment Report

96
96%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The AI claims regarding WAINUA’s adult indication and the recommended 45 mg once-monthly subcutaneous dosing/administration are directly supported by the provided label sections with no contradictions.


Category Scores

Indication
100
Excellent
Dosage
96
Excellent
Indication
100
Excellent

Accurate Statements

WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Indications and Usage: "WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults."
The recommended dosing is 45 mg administered by subcutaneous injection once monthly.
Dosage and Administration (2.1): "The recommended dosage of WAINUA is 45 mg administered by subcutaneous injection once monthly."
Administration details as specified in the label are consistent (autoinjector/prefilled syringe entire contents; subcutaneous injection sites; rotate injection site; avoid specified areas).
Dosage and Administration (2.2): includes full contents of one autoinjector/prefilled syringe; injection in upper thigh or abdomen; upper arm if administered by HCP/caregiver; rotate injection site; avoid 2 inches (5 cm) around navel and areas with specified skin characteristics.

Unsupported Statements


Contradictions


Important Omissions


Safety Assessment

Potential Patient Risk: Low
The evaluated claims are limited to on-label indication and routine recommended dosing/administration. No additional safety-critical instructions (e.g., missed dose handling, vitamin A warning) were claimed beyond the core dosing/administration alignment.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue

Suggested Improvement

Drug Brand Mention Assessment

Branding Score
38
Visibility
36
Mentioned
Ranking
#1
Sentiment
41
Recommendation Status
mentioned only
Brand Perception
Best Known For

targeting the production of transthyretin (TTR)


Core Claims
  • Eplontersen sodium is a prescription medicine
  • It is intended for people with specific hereditary transthyretin amyloidosis (hATTR)
  • It works by targeting production of transthyretin (TTR)
  • Lowering circulating TTR helps address amyloid buildup from misfolded TTR proteins
  • "Eplontersen sodium" is the drug substance and brand names can vary by country
Differentiators
  • Designed to reduce the amount of transthyretin made by the body
  • Lowering circulating TTR helps address amyloid formed from misfolded TTR proteins

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Drugs.com 25%
50 # No